273 related articles for article (PubMed ID: 15770010)
1. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
Chan AT; Tranah GJ; Giovannucci EL; Hunter DJ; Fuchs CS
J Natl Cancer Inst; 2005 Mar; 97(6):457-60. PubMed ID: 15770010
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge M; Armitage N; Shepherd V; Popat S; Houlston RS;
Clin Cancer Res; 2006 Nov; 12(21):6585-9. PubMed ID: 17085674
[TBL] [Abstract][Full Text] [Related]
4. Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women.
Wei EK; Giovannucci E; Selhub J; Fuchs CS; Hankinson SE; Ma J
J Natl Cancer Inst; 2005 May; 97(9):684-92. PubMed ID: 15870439
[TBL] [Abstract][Full Text] [Related]
5. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
Ulrich CM; Whitton J; Yu JH; Sibert J; Sparks R; Potter JD; Bigler J
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):616-9. PubMed ID: 15767339
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps.
Ulrich CM; Bigler J; Sparks R; Whitton J; Sibert JG; Goode EL; Yasui Y; Potter JD
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):889-93. PubMed ID: 15159324
[TBL] [Abstract][Full Text] [Related]
7. GSTP1 and GSTA1 polymorphisms interact with cruciferous vegetable intake in colorectal adenoma risk.
Tijhuis MJ; Wark PA; Aarts JM; Visker MH; Nagengast FM; Kok FJ; Kampman E
Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2943-51. PubMed ID: 16365014
[TBL] [Abstract][Full Text] [Related]
8. Folate intake, MTHFR C677T polymorphism, alcohol consumption, and risk for sporadic colorectal adenoma (United States).
Boyapati SM; Bostick RM; McGlynn KA; Fina MF; Roufail WM; Geisinger KR; Hebert JR; Coker A; Wargovich M
Cancer Causes Control; 2004 Jun; 15(5):493-501. PubMed ID: 15286469
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for advanced colorectal adenomas: a pooled analysis.
Terry MB; Neugut AI; Bostick RM; Sandler RS; Haile RW; Jacobson JS; Fenoglio-Preiser CM; Potter JD
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):622-9. PubMed ID: 12101109
[TBL] [Abstract][Full Text] [Related]
11. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.
Samowitz WS; Wolff RK; Curtin K; Sweeney C; Ma KN; Andersen K; Levin TR; Slattery ML
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):894-901. PubMed ID: 16797247
[TBL] [Abstract][Full Text] [Related]
12. Aspirin and the risk of colorectal cancer in women.
Giovannucci E; Egan KM; Hunter DJ; Stampfer MJ; Colditz GA; Willett WC; Speizer FE
N Engl J Med; 1995 Sep; 333(10):609-14. PubMed ID: 7637720
[TBL] [Abstract][Full Text] [Related]
13. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland.
Macarthur M; Sharp L; Hold GL; Little J; El-Omar EM
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1613-8. PubMed ID: 16030091
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study.
Ueda N; Maehara Y; Tajima O; Tabata S; Wakabayashi K; Kono S
Cancer Sci; 2008 Mar; 99(3):576-81. PubMed ID: 18167131
[TBL] [Abstract][Full Text] [Related]
15. Selenium and colorectal adenoma: results of a pooled analysis.
Jacobs ET; Jiang R; Alberts DS; Greenberg ER; Gunter EW; Karagas MR; Lanza E; Ratnasinghe L; Reid ME; Schatzkin A; Smith-Warner SA; Wallace K; MartÃnez ME
J Natl Cancer Inst; 2004 Nov; 96(22):1669-75. PubMed ID: 15547179
[TBL] [Abstract][Full Text] [Related]
16. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):502-8. PubMed ID: 16537708
[TBL] [Abstract][Full Text] [Related]
17. Inflammation-related gene polymorphisms and colorectal adenoma.
Gunter MJ; Canzian F; Landi S; Chanock SJ; Sinha R; Rothman N
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1126-31. PubMed ID: 16775170
[TBL] [Abstract][Full Text] [Related]
18. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk.
Peters U; Hayes RB; Chatterjee N; Shao W; Schoen RE; Pinsky P; Hollis BW; McGlynn KA;
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):546-52. PubMed ID: 15066918
[TBL] [Abstract][Full Text] [Related]
19. XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk.
Stern MC; Siegmund KD; Corral R; Haile RW
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):609-15. PubMed ID: 15767338
[TBL] [Abstract][Full Text] [Related]
20. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer.
Ma J; Stampfer MJ; Giovannucci E; Artigas C; Hunter DJ; Fuchs C; Willett WC; Selhub J; Hennekens CH; Rozen R
Cancer Res; 1997 Mar; 57(6):1098-102. PubMed ID: 9067278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
